These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27672335)

  • 1. The association of PTEN hypermethylation and breast cancer: a meta-analysis.
    Luo S; Chen J; Mo X
    Onco Targets Ther; 2016; 9():5643-50. PubMed ID: 27672335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.
    Lu DG; Ma YM; Zhu AJ; Han YW
    Oncotarget; 2017 Mar; 8(13):22166-22174. PubMed ID: 27825140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.
    Song XY; Li BY; Zhou EX; Wu FX
    Onco Targets Ther; 2016; 9():5339-47. PubMed ID: 27616890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review.
    Lu YM; Cheng F; Teng LS
    Sci Rep; 2016 Sep; 6():32723. PubMed ID: 27620353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
    Su Y; Wang X; Li J; Xu J; Xu L
    Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
    Huang R; Ding P; Yang F
    Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients: A meta-analysis.
    Xu F; Zhang C; Cui J; Liu J; Li J; Jiang H
    Medicine (Baltimore); 2017 Sep; 96(36):e8000. PubMed ID: 28885360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.
    Li S; Shen Y; Wang M; Yang J; Lv M; Li P; Chen Z; Yang J
    Oncotarget; 2017 May; 8(19):32043-32054. PubMed ID: 28410191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance and potential drug target of RUNX3 in breast cancer.
    Yu YY; Chen C; Kong FF; Zhang W
    Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of RARβ2, DAPK, hMLH1, p14, and p15 is associated with progression of breast cancer: A PRISMA-compliant meta-analysis.
    Qi M; Xiong X
    Medicine (Baltimore); 2018 Dec; 97(51):e13666. PubMed ID: 30572486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic and prognostic value of
    Sun Z; Liu J; Jing H; Dong SX; Wu J
    Oncotarget; 2017 Oct; 8(51):89142-89148. PubMed ID: 29179506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic significance of
    Wu X; Yao X; Cao Q; Wu Z; Wang Z; Liu F; Shen L
    Cancer Manag Res; 2019; 11():857-864. PubMed ID: 30697077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological significance of WIF1 hypermethylation in NSCLC, a meta-analysis and literature review.
    Guo H; Zhou S; Tan L; Wu X; Wu Z; Ran R
    Oncotarget; 2017 Jan; 8(2):2550-2557. PubMed ID: 27911280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
    Huang J; Luo JY; Tan HZ
    PLoS One; 2019; 14(10):e0222772. PubMed ID: 31574102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis.
    Lee JS
    Virchows Arch; 2007 Jun; 450(6):637-42. PubMed ID: 17479284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Human mutL Homolog 1 (hMLH1) Hypermethylation and Colorectal Cancer: A Meta-Analysis.
    Zhang HF; Lu YW; Xie ZR; Wang KH
    Med Sci Monit; 2017 Jun; 23():3026-3038. PubMed ID: 28635682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN in kidney cancer: A review and meta-analysis.
    Que WC; Qiu HQ; Cheng Y; Liu MB; Wu CY
    Clin Chim Acta; 2018 May; 480():92-98. PubMed ID: 29408173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.